Canadian healthcare group Concordia (NASDAQ:CXRX, TSE:CXR) is to pay US$3.5bn to acquire Amdipharm Mercury in a cash plus stock deal.
European private equity group Cinven has agreed to sell Amdipharm for £800mln (circa US$1.2bn) plus 8.49mln common shares of Concordia, valued at around US$0.7bn, while Concordia will also take on around US$1.4bn of the acquired company’s debt.
14:53 Netflix fueled by original programming, even as its costs hold earnings back, analysts say17
14:56 Read what Steven Mnuchin will say at his Treasury confirmation hearing18
10:05 Why you'll now pay 25% more for apps on your iPhone21
09:29 Tobacco giant BAT buys out US firm Reynolds in mega-deal19